

Such an effect may prove useful as a therapeutic agent to reduce production and/or biological activity of NO_x.

3075

1α Growth Factor Upregulates the Expression of Nitric Oxide in Native and Cultured Endothelial Cells

Uwe B Schen-Kerth, Rudi Busse, Zentrum der Physiologie, Frankfurt Am

Growth factor (VEGF) has been shown to accelerate re-endothelialization of thickening in balloon-inflated arteries. Since endothelium-derived nitric oxide (NO) relaxes smooth muscle growth, we tested whether VEGF enhances nitric oxide in endothelial cells. Experiments were performed with primary cultures of human skin cells (HUVEC) and with endothelium-derived rat aortic rings. Nitric oxide creation was assessed by RT-PCR and Western blot analyses, and NOS II (α-nitro-*cGMP*) in HUVEC and endothelium-dependent relaxations in aortic rings to VEGF-165 (100 ng/ml) for 48 h led to an increase in NOS II and in the basal level of cGMP (2.2 ± 0.5 fold) whereas that evoked by (SNP) was unaffected. VEGF treatment increased in a concentration-
OD 30 mRNA levels within 2 h which remained elevated for the next 48 h. 1 of VEGF on NOS II mRNA was abolished by protein synthesis inhibitor and translation AI and was not prevented by the inhibitor of transcription factor of sonic hedgehog to VEGF for 7 h (a specialized endothelium-dependent relaxant whereas those to SNP were unaffected). Increased levels of NOS II are found in VEGF-treated aortic rings. These findings indicate that VEGF expression in native and cultured endothelial cells. This effect is mediated via cGMP pathway(s) and seems to be due to the stabilization of basal generation of endothelial nitric oxide may contribute to the protective VEGF-induced arterial thickening.

3076

Inhibition of Pin, A Protein Inhibitor of Neuronal Nitric Oxide Synthase

Michael T Greenwood, Quasim El-Danaf, Yang Guo, McGill University.

neuronal nitric oxide synthase (nNOS) has been localized to the inner membrane of skeletal muscle dystrophy, nNOS is localized to the cytosol and has been gross of the disease. A protein inhibitor of nNOS (PIN) which specifically vents nNOS dimerization has recently been cloned. The 89 residue PIN, requires the biochemical activity of nNOS. We have, therefore, examined, analysis, the distribution and regulation PIN transcript in skeletal muscle pathophysiological conditions where nNOS expression has been shown to be (A) was detected in tibial muscles of normal rats but the highest level of PIN in skeletal muscle which has the lowest nNOS expression. In the OS and PIN expressions were elevated in embryos compared with adult significant developmental regulation. In embryonic rats (20 mg/kg E10) OS and PIN expressions were elevated in tibial muscles within 12 hours of we further examined the level of PIN and nNOS in the mouse myoblast cell growing myoblast, significant PIN mRNA expression was detected. High PIN was maintained following the induction of myoblast fusion and in the muscle cells indicate that PIN is expressed in various skeletal muscles *in vivo* and and its expression correlates with that of nNOS. Moreover PIN mRNA in pathophysiological conditions such as septic shock.

3077

Arteron Regulatory Factor-1 and Nuclear Factor κ B During S Transcription

Zaragoza, Audrey McMillan, Charles J Lowenstein, Johns Hopkins.

oxide synthase (iNOS) is expressed in a variety of inflammatory disorders in system, and iNOS expression is regulated at the transcriptional level. We molecular basis for the synergistic induction of the iNOS gene elicited by TNF-α and IFN-γ activate NF-κ B and IRF-1 in macrophages, and these transcription factor to the κ B and the IRE sites in the iNOS promoter to elicit iNOS gene that IRF-1 and NF-κ B interact with each other. Co-immunoprecipitation that IRF-1 and NF-κ B are bound to each other only in stimulated cells that experiments show that IRF-1 and NF-κ B interact when binding to DNA target region. The proteins bound to a κ B site include not only NF-κ B so IRF-1. Similarly, the proteins bound to an IRE site include not only IRF-1. These results demonstrate the existence of a physical interaction between proteins *in vivo*. To explore the functional consequences of the interaction of NF-κ B, we examined their ability to affect the structure of the iNOS transcription factors distant promoter DNA structure at the site of binding by

3078 Aerosol Nitric Oxide Synthase Gene Transfer in Acute Hypoxic Pulmonary Hypertension

Werner Budz, Cardiac Unit, Leuven Belgium; Zaragoza, Ning, VIB, Leuven Belgium; Nazarach Van Pelt, Cardiac Unit, Leuven Belgium; Rick Lyons, Univ of New Mexico, Albuquerque, NM; Robert D Gerard, VIB, Leuven Belgium; Søren Jørgensen, Cardiac Unit, Leuven Belgium

Nitric oxide (NO), a vasodilator involved in the regulation of pulmonary vascular tone, is synthesized by a class of enzymes, NO synthases (NOS). We have previously shown that zymosan-induced overexpression of the calcium-dependent type III NOS in rat lungs reduces acute hypoxic pulmonary vasoconstriction. To evaluate the level and duration of NO production following NOS gene transfer, we measured exhaled NO by chemiluminescence in rats infected with adenovirus expressing the calcium-dependent type II NOS (4×10^9 pfu/ml, $n=7$), type III NOS ($n=6$), or control virus expressing no rat gene (AdPRS, $n=7$). Exhaled NO was increased in NOS II-infected rats compared to NOS-III-infected rats at 24 h (55 ppb vs 47 ppb), 4 d (52 ppb vs 26 ppb), and 7 d (31 ppb vs 22 ppb), but no longer at 10 d. The levels of NO in AdPRS-infected rats were significantly lower at all time points (15±8 ppb at 24 h, 6±3 ppb at 4 d and 7±1 ppb at 7 d). To investigate whether increased pulmonary NO production after NOS II gene transfer was associated with greater inhibition of hypoxic pulmonary vasoconstriction, mean pulmonary artery pressure (PAP, mmHg) was measured during acute hypoxia ($50\% \text{O}_2$, 40, 25 mmHg) in rats 4 d after infection with NOS II ($n=7$), NOS III ($n=6$), or control virus ($n=6$). Acute hypoxia increased PAP from 19±4 to 21±5 mmHg in NOS II-infected rats compared to 23±2 mmHg in NOS III-infected and 26±2 mmHg in control virus-infected rats with no significant effect on systemic blood pressure. Thus, pulmonary NOS II gene transfer significantly increases pulmonary exhaled NO production for at least 7 days and is associated with a greater inhibition of acute hypoxic pulmonary vasoconstriction. Single intrabronchial NOS II gene transfer may be a promising therapy for pulmonary hypertension.

3079 Intercouncil Review: Angiogenesis and Cell Proliferation: Wednesday Morning Convention Center Room 104A-B Abstracts 3079 - 3088

3079

A Murine Model of Accelerated Diabetic Atherosclerosis: Suppression By Soluble Receptor For Advanced Glycation Endproducts

Lee Park, Kathleen G Ruman, Kenneth J Lee Yen, Li, Michael D Greenberg, Luis Ferrer Jr, David M Stern, Ann Marie Schmidt, Columbia University, New York, NY

Multiple studies suggest that lipid-independent mechanisms contribute to the development of cardiovascular disease in diabetes. Under conditions of sustained hyperglycemia, nonenzymatic glycation and oxidation of proteins and lipids results in the irreversible formation of Advanced Glycation Endproducts (AGEs) which accumulate in diabetic plasma and tissues. AGEs interact with cellular receptors such as RAGE, the Receptor for AGEs, and induce vascular cell dysfunction. The extracellular portion of RAGE (one V-type and two C-type immunoglobulin domains) is a soluble fragment (sRAGE) which we propose may bind AGEs and block their interaction with their cell-surface receptor. We previously demonstrated a 3.7-fold increase in atherosclerotic lesion area in streptozotocin-treated apolipoprotein E deficient mice to control, with enhanced accumulation of AGEs and increased expression of RAGE in the vasculature. To test if blockade of AGE-RAGE would suppress accelerated atherosclerosis, diabetic apo E deficient mice were treated for six weeks with sRAGE (20 μg/day, intraperitoneally) or equimolar mouse serum albumin (400 μg/day MSA). Mean lesion area was decreased 1.8-fold ($p=0.016$) in mice treated with sRAGE (150.04±18.549 μ m^2) vs MSA (271.00±16.721 μ m^2). No difference was observed at a low dosage of 3 μg/day, enhanced anti-atherosclerotic effects were observed with higher doses of 30-40 μg/day. Since serum glucose and HbA_{1c} levels revealed persistent hyperglycemia in both groups. There were no differences in levels of total cholesterol and triglyceride, and FPLC analysis yielded identical lipid profiles. Taken together, these data suggest that enhanced AGE-RAGE interaction likely plays a critical role in the pathogenesis of accelerated atherosclerosis in diabetes.

3080

Essential Role of Endothelial Nitric Oxide Synthase in Angiogenesis *In Vivo*

Torsten Murenko, Takeshi Aoshima, Mercy Silver, Marianne Kearney, Marcella Mayer, Xiong Yang, Donghua Chen, Dongchen Chen, James F Synts, St Elizabeth's Medical Center, Boston, MA; Paul L Huang, Massachusetts General Hospital, Boston, MA; Jeffrey M Isner, St Elizabeth's Medical Center, Boston, MA

Circulation Supplement 1997
Abstract 3079